Press Releases |News

03/09/2023

Cardiology

Tempus Announces the Acquisition of Mpirik

Tempus expands further into revolutionizing cardiovascular disease care Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the acquisition of Mpirik, a cardiology-focused healthcare technology company specializing in data-driven patient screening, automated care coordination, and clinical research. The combination of Mpirik's Cardiac Intelligence® platform...

03/08/2023

Tempus Introduces TAAP, a Collaborative Research Platform to Develop and Deploy Algorithmic Diagnostics

Tempus, a leader in artificial intelligence and precision medicine, today announced its Tempus AI Advisors Program (TAAP), a platform that provides investigators access to the company’s multimodal database to enable development of novel clinical, molecular, and imaging-based algorithms to improve clinical care. Through TAAP, Tempus is fostering...

02/28/2023

Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and deve...

02/23/2023

Tempus Announces New Multi-omics Collaboration with Actuate Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc. (Actuate), a clinical-stage biopharmaceutical company, to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests wi...

01/05/2023

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is cur...

12/15/2022

Oncology

Fight Colorectal Cancer Funds Tempus Research Fellow to Identify Gaps in Colorectal Cancer Research

Fight Colorectal Cancer (Fight CRC) announced today that they have committed $150,000 per year for a three-year research fellowship to study clinical data at Tempus, a leader in artificial intelligence and precision medicine. The awarded researcher will receive access to Tempus de-identified datasets and analytical platform to ide...

12/06/2022

Oncology

Tempus Announces Six Abstracts Accepted for Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the 2022 San Antonio Breast Cancer Symposium, which convenes from December 6-10, in San Antonio, Texas. Tempus continues to be a leader in advancing breast cancer research, demonstrated in the six abstract...

11/09/2022

Oncology

Tempus Announces Six Abstracts Accepted for Presentation at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, which convenes in Boston, Massachusetts, from November 8-12, 2022. Tempus continues to be a leader in advancing immunotherapy research...

11/04/2022

Cardiology

Tempus Announces Six Abstracts Accepted for Presentation at the American Heart Association Scientific Sessions 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts, resulting from its strategic partnership with Geisinger, were accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2022, which convenes in Chicago, Illinois from November 5-7, 2022. This is the fourth year that Tempus has presented w...

11/03/2022

Tempus Launches First Cardiology Prospective Study for its AI-Enabled Predictive Tests

In collaboration with iRhythm, Tempus is studying its predictive, AI-enabled algorithmic tests via a network of researchers to determine the impact of detecting patients at increased risk of developing cardiovascular disease Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of a multi-center study titled, ...

NEWS

Press Releases

Media Coverage

Additional Partnerships